Shalby

Which are the latest news on Shalby?

Why is Shalby Ltd. falling/rising?

As of 05-Sep, Shalby Ltd. is facing a slight decline in its stock price at 152.75, with significant underperformance over various time frames and a year-to-date drop of -24.88%. Despite some positive quarterly sales, weak long-term fundamentals and declining investor participation contribute to the stock's downward pressure.

As of 05-Sep, Shalby Ltd. is experiencing a slight decline in its stock price, currently at 152.75, which reflects a change of -0.1 (-0.07%). The stock has underperformed significantly over various time frames, with a year-to-date decline of -24.88% compared to a -10.21% drop in the benchmark Sensex. Over the past year, Shalby Ltd. has generated a return of -22.09%, while the Sensex has only declined by -5.21%. <BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.97%, but it is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by -14.06% against the 5-day average, which suggests a lack of confidence among investors.<BR><BR>While there are some positive factors, such as the highest quarterly net sales at Rs 331.22 crore and a significant growth in profit after tax, the long-term fundamentals appear weak. The company has shown a -5.31% CAGR growth in operating profits over the last five years and a low return on equity of 5.25%, indicating low profitability per unit of shareholders' funds. Furthermore, the minimal stake held by domestic mutual funds (only 0.03%) may reflect their lack of confidence in the stock's current valuation or business prospects.<BR><BR>Overall, the combination of consistent underperformance against benchmarks, declining investor participation, and weak long-term fundamentals contributes to the downward pressure on Shalby Ltd.'s stock price.

Who are in the management team of Shalby?

The management team of Shalby includes Vikram Shah as Chairman & Managing Director, Sushobhan Dasgupta as Vice Chairman, and Tushar Shah as Company Secretary. The board also features independent directors such as Shyamal S Joshi, Umesh Menon, and others, who contribute to the company's strategic direction and governance.

The management team of Shalby includes the following individuals:<BR><BR>1. **Vikram Shah** - Chairman & Managing Director<BR>2. **Sushobhan Dasgupta** - Vice Chairman<BR>3. **Tushar Shah** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- **Shyamal S Joshi**<BR>- **Umesh Menon**<BR>- **Ashok Bhatia**<BR>- **Tej Malhotra**<BR>- **Sujana Shah**<BR>- **Vijay Kishanlal Kedia**<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

What does Shalby do?

Shalby Ltd. is a small-cap company in the hospital industry, reporting net sales of 331 Cr and a net profit of 11 Cr for June 2026. It was incorporated in 2004 and became a public limited company in 2006, with a current market cap of INR 1,661 Cr.

Overview:<BR>Shalby Ltd. operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>Shalby Ltd. was originally incorporated as 'Shalby Hospital Private Limited' in 2004, transitioned to a public limited company in 2006, and underwent several name changes, with the latest being 'Shalby Limited' in 2008. The most recent quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 331 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 11 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,661 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 42.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.51 <BR>Return on Equity: 3.72% <BR>Price to Book: 1.67 <BR><BR>Contact Details:<BR>Address: Opp Karnawati Club, Sarkhej Gandhinagar Highway Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-40203000 <BR>Email: companysecretary@shalby.in <BR>Website: http://www.shalby.org

Who are the peers of the Shalby?

Shalby's peers include Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, GPT Healthcare, Asarfi Hospital, Unihealth Hosp, and Chandan Healthca. In terms of performance, KMC Speciality leads with a 1-year return of 97.77%, while Shalby has a return of -20.36%.

Peers: The peers of Shalby are Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, GPT Healthcare, Asarfi Hospital, Unihealth Hosp, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Asarfi Hospital, and Unihealth Hosp, and the rest. Growth is Excellent at Jeena Sikho, Unihealth Hosp, and Chandan Healthca, while Good growth is noted at Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, and Asarfi Hospital, and the rest. Below Average growth is seen at Shalby and KMC Speciality. Excellent capital structure is present at Jeena Sikho, Indrapr.Medical, KMC Speciality, and GPT Healthcare, while Good capital structure is noted at Shalby, Artemis Medicare, Asarfi Hospital, and Chandan Healthca, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMC Speciality at 97.77%, while Jeena Sikho has the lowest at -27.85%. Shalby's 1-year return is -20.36%, which is higher than Jeena Sikho's but lower than KMC Speciality's. Additionally, the six-month returns for Jeena Sikho, Indrapr.Medical, and GPT Healthcare are negative.

How big is Shalby?

As of 31st August, Shalby Ltd. has a market capitalization of 1,661.00 Cr, with recent Net Sales of 1,176.23 Cr and a Net Profit of 39.33 Cr. Shareholder's Funds are 1,005.24 Cr and Total Assets are valued at 1,839.13 Cr as of March 2026.

As of 31st August, Shalby Ltd. has a market capitalization of 1,661.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Shalby Ltd. reported Net Sales of 1,176.23 Cr and a Net Profit of 39.33 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, where Shareholder's Funds amounted to 1,005.24 Cr and Total Assets were valued at 1,839.13 Cr.

Should I buy, sell or hold Shalby Ltd.?

Are Shalby Ltd. latest results good or bad?

Shalby Ltd.'s latest results are concerning, showing a significant net profit increase due to a tax reversal, but with declining operating margins and negative cash flow from operations. Overall, the company's financial health appears under stress, with poor return on equity and underperformance compared to the hospital sector.

Shalby Ltd.'s latest results present a mixed picture, leaning towards the negative side. While the company reported a significant increase in net profit of ₹18.32 crore for Q4 FY26, this figure was heavily influenced by a tax reversal that artificially inflated profits. The underlying operational performance is concerning, as operating margins have contracted sharply from 14.58% in Q2 FY26 to just 10.21% in Q4 FY26, indicating deteriorating core business performance.<BR><BR>Additionally, the stock has underperformed the hospital sector significantly, declining 12.73% over the past year compared to the sector's gain of 20.18%. The return on equity (ROE) has fallen to a troubling 0.45%, suggesting that the company is generating virtually no returns on shareholder capital. <BR><BR>Moreover, the company's reliance on non-operating income, which constituted a large portion of profit before tax, raises questions about the sustainability of its earnings. Cash flow from operations has turned negative, further highlighting operational inefficiencies.<BR><BR>In summary, while there are some positive indicators like revenue growth, the overall financial health of Shalby Ltd. appears to be under stress, making the latest results more concerning than promising.

When is the next results date for Shalby Ltd.?

The next results date for Shalby Ltd. is 12 August 2026.

The next results date for Shalby Ltd. is scheduled for 12 August 2026.

Is Shalby technically bullish or bearish?

As of December 1, 2025, the market trend has shifted to mildly bearish, supported by bearish MACD readings, Bollinger Bands, and Dow Theory, despite some daily moving averages indicating mild bullishness.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating bearish momentum, along with Bollinger Bands and KST both signaling bearish conditions. The Dow Theory also supports a mildly bearish outlook on both weekly and monthly time frames. Although daily moving averages show a mildly bullish signal, the overall technical indicators suggest a bearish sentiment prevailing in the market.

How has been the historical performance of Shalby?

Shalby's historical performance shows strong revenue growth, with net sales increasing to 1,086.96 Cr by Mar'25, but rising expenditures led to a decline in operating profit and profit after tax, which fell to 1.92 Cr. Additionally, cash flow from operating activities turned negative in Mar'25, indicating potential liquidity issues.

Answer:<BR>The historical performance of Shalby shows significant growth in net sales and operating income over the years, with net sales increasing from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25. Total operating income followed a similar trend, reaching 1,086.96 Cr in Mar'25, up from 804.92 Cr in Mar'23. However, total expenditure also rose, climbing from 344.48 Cr in Mar'21 to 954.35 Cr in Mar'25, which impacted the operating profit, which decreased from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. Profit before tax saw a decline from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, leading to a profit after tax of only 1.92 Cr in Mar'25 compared to 83.50 Cr in Mar'24. The earnings per share dropped significantly from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased from 1,193.54 Cr in Mar'22 to 1,703.65 Cr in Mar'25, while total liabilities also rose from 1,193.54 Cr to 1,703.65 Cr in the same period. Cash flow from operating activities turned negative in Mar'25 at -4.00 Cr, contrasting with positive cash flows in previous years.<BR><BR>Breakdown:<BR>Shalby's financial performance has shown a robust increase in net sales, which rose from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25, indicating strong revenue growth. Total operating income mirrored this growth, reaching 1,086.96 Cr in Mar'25. However, total expenditure surged to 954.35 Cr in Mar'25, leading to a decline in operating profit from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. This decline was further reflected in profit before tax, which fell from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, resulting in a profit after tax of just 1.92 Cr in Mar'25. The earnings per share also saw a drastic drop from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased significantly to 1,703.65 Cr in Mar'25, while total liabilities rose correspondingly, indicating a growing debt load. Cash flow from operating activities turned negative in Mar'25, contrasting with positive cash flows in prior years, highlighting potential liquidity challenges.

Is Shalby overvalued or undervalued?

As of October 8, 2025, Shalby is considered very attractive and undervalued, with a PE ratio of -2742.37, a price-to-book value of 2.76, and strong long-term returns of 89.9% and 190.67% over three and five years, respectively, despite recent underperformance compared to peers like Apollo Hospitals and Max Healthcare.

As of 8 October 2025, the valuation grade for Shalby has moved from attractive to very attractive. The company is currently considered undervalued, particularly given its extreme PE ratio of -2742.37 and a price-to-book value of 2.76. Other notable ratios include an EV to EBITDA of 23.96 and a ROCE of 4.99%. <BR><BR>In comparison to its peers, Shalby stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 70.05, and Max Healthcare, which is at 92.31. Despite the negative sentiment reflected in the recent stock performance, where Shalby has underperformed the Sensex over the past week, its long-term returns over three and five years show a robust growth of 89.9% and 190.67%, respectively, reinforcing its undervaluation narrative.

Who are the top shareholders of the Shalby?

The top shareholder of Shalby is the Shah Family Trust, led by Dr. Vikram Shah, with a 34.73% stake. Other notable shareholders include 38 foreign institutional investors with 5.2% and First Water Fund, the largest public shareholder, at 1.77%.

The top shareholders of Shalby include the Shah Family Trust, represented by Dr. Vikram Shah, who holds the largest stake at 34.73%. The company is primarily owned by its promoters, with no pledged promoter holdings. Additionally, there are 38 foreign institutional investors (FIIs) who collectively hold 5.2% of the shares. The highest public shareholder is First Water Fund, with a holding of 1.77%. Individual investors account for 11.2% of the total shareholding.

Has Shalby declared dividend?

Yes, Shalby Ltd. has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 19, 2024. Despite recent negative returns in the short term, long-term performance shows positive trends, particularly over the last five years.

Shalby Ltd. has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.66%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Shalby experienced a price return of -24.69%, with no dividend return, resulting in a total return of -24.69%.<BR><BR>Over the past year, the price return was -29.77%, with a dividend return of 0.43%, leading to a total return of -29.34%.<BR><BR>In the 2-year period, the price return was 28.62%, with a dividend return of 1.50%, resulting in a total return of 30.12%.<BR><BR>For the 3-year period, Shalby had a price return of 57.96%, a dividend return of 3.50%, culminating in a total return of 61.46%.<BR><BR>In the last 4 years, the price return was 6.68%, with a dividend return of 2.54%, leading to a total return of 9.22%.<BR><BR>Finally, over the 5-year period, Shalby achieved a price return of 167.0%, a dividend return of 7.00%, resulting in a total return of 174.0%.<BR><BR>Overall, while Shalby has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last year and six months. However, the longer-term returns show a more positive trend, especially over the 5-year period.